Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved ...

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive ...

Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia ...

Every year, approximately 700 Canadians are diagnosed with chronic myeloid leukemia (CML), a type of blood cancer that starts in the bone marrow. While there is no cure, people with CML today have a ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic ...

In 2020, leukemia (cancer of the blood) accounted for approximately 2.5 per cent of all new cancer cases and 3.1 per cent of deaths globally. Of these, chronic myeloid leukemia (CML) is a subtype that ...

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...